iRhythm Technologies, Inc. (NASDAQ:IRTC) Shares Sold by Fox Run Management L.L.C.

Fox Run Management L.L.C. lowered its position in shares of iRhythm Technologies, Inc. (NASDAQ:IRTC) by 46.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,837 shares of the company’s stock after selling 3,278 shares during the quarter. Fox Run Management L.L.C.’s holdings in iRhythm Technologies were worth $346,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of IRTC. KLP Kapitalforvaltning AS acquired a new position in shares of iRhythm Technologies in the 4th quarter worth approximately $595,000. Sei Investments Co. grew its position in iRhythm Technologies by 6.1% in the fourth quarter. Sei Investments Co. now owns 318,653 shares of the company’s stock worth $28,733,000 after buying an additional 18,358 shares during the last quarter. Xponance Inc. bought a new position in shares of iRhythm Technologies in the fourth quarter valued at $203,000. Intech Investment Management LLC lifted its position in shares of iRhythm Technologies by 57.8% during the 4th quarter. Intech Investment Management LLC now owns 14,927 shares of the company’s stock valued at $1,346,000 after acquiring an additional 5,467 shares during the last quarter. Finally, Cibc World Markets Corp bought a new stake in shares of iRhythm Technologies during the 4th quarter worth $264,000.

iRhythm Technologies Trading Down 1.5 %

NASDAQ IRTC opened at $104.96 on Thursday. The company has a market capitalization of $3.30 billion, a PE ratio of -28.84 and a beta of 1.36. iRhythm Technologies, Inc. has a 1-year low of $55.92 and a 1-year high of $128.52. The company has a current ratio of 6.27, a quick ratio of 6.12 and a debt-to-equity ratio of 9.00. The firm’s fifty day simple moving average is $108.18 and its 200-day simple moving average is $89.58.

iRhythm Technologies (NASDAQ:IRTC) last posted its quarterly earnings results on Thursday, February 20th. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.30. The company had revenue of $164.33 million during the quarter, compared to the consensus estimate of $158.30 million. iRhythm Technologies had a negative return on equity of 118.83% and a negative net margin of 19.14%. As a group, sell-side analysts anticipate that iRhythm Technologies, Inc. will post -1.98 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on IRTC. Wells Fargo & Company upped their target price on iRhythm Technologies from $86.00 to $104.00 and gave the company an “equal weight” rating in a report on Friday, February 21st. The Goldman Sachs Group upped their price objective on shares of iRhythm Technologies from $91.00 to $124.00 and gave the company a “neutral” rating in a research note on Monday, February 24th. Oppenheimer lifted their target price on shares of iRhythm Technologies from $105.00 to $120.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. Needham & Company LLC upped their price target on shares of iRhythm Technologies from $125.00 to $138.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Finally, Truist Financial lifted their price objective on shares of iRhythm Technologies from $111.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, iRhythm Technologies currently has a consensus rating of “Moderate Buy” and a consensus price target of $119.73.

iRhythm Technologies Company Profile

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.